Elevation Oncology, Inc. is a New York-based biopharmaceutical firm focused on developing treatments for cancer patients with specific genetic profiles. The company's primary program is the seribantumab, an anti-HER3 monoclonal antibody now undergoing a Phase II CRESTONE trial. Elevation Oncology, Inc. was founded in 2019 and focuses solely on oncology therapeutics.